The New Jersey Chapter held its 40th Spring Symposium at Rutgers RWJ Medical School June 28. The theme of the symposium was Clinical Trials for Rare Diseases and Pediatric Populations: Challenges in Design and Analysis. 

Approximately 70 people attended the following presentations: 

• Gary Rosner of The Johns Hopkins University, “Meta-Analysis of Rare Adverse Events in Randomized Clinical Trials:  Bayesian and Frequentist Methods”
• Hui Quan of Sanofi, “A Case Study of Phase II/III Seamless Adaptive Design in a Rare Disease Area”
• Cong Chen of Merck, “Statistical Considerations on Early-to-Late Transition of Oncology Projects
• Peter Messenbrink of Novartis, “Innovation in Pediatric Trial Design in Rare Autoimmune Diseases
• Satrajit Roychoudhury of Pfizer Inc., “Incorporating Adult Clinical Data into Pediatric Clinical Trials:  A Robust Bayesian Approach
• James Travis of FDA, “Pediatric Drug Development: A Regulatory Perspective 

The following three posters were also on display: 

• Ken Goldberg of Johnson & Johnson, “Robust Statistical Methods for Defining Cut Points Based on Tolerance Intervals”
• Dirk Moore of Rutgers, “Using Competing Risks Survival Data from the SEER-Medicare Database to Power a Prostate Cancer Randomized Clinical Trial”
• Steve Ascher, “ASA NJ Chapter Spring Symposium—40th Anniversary: A Brief History”

During lunch, NJ Chapter Secretary Steve Ascher gave a brief presentation on the history of the Spring Symposium, where a celebratory cake was cut to commemorate the 40th anniversary of the event.